These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1084 related articles for article (PubMed ID: 28596306)

  • 21. Mendelian randomisation and the goal of inferring causation from observational studies in the vision sciences.
    Plotnikov D; Guggenheim JA
    Ophthalmic Physiol Opt; 2019 Jan; 39(1):11-25. PubMed ID: 30628743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings.
    Lind L; Ingelsson M; Sundstrom J; Ärnlöv J
    Open Heart; 2021 Sep; 8(2):. PubMed ID: 34518286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment.
    Benn M; Nordestgaard BG
    Cardiovasc Res; 2018 Jul; 114(9):1192-1208. PubMed ID: 29471399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applying Mendelian randomization to appraise causality in relationships between nutrition and cancer.
    Wade KH; Yarmolinsky J; Giovannucci E; Lewis SJ; Millwood IY; Munafò MR; Meddens F; Burrows K; Bell JA; Davies NM; Mariosa D; Kanerva N; Vincent EE; Smith-Byrne K; Guida F; Gunter MJ; Sanderson E; Dudbridge F; Burgess S; Cornelis MC; Richardson TG; Borges MC; Bowden J; Hemani G; Cho Y; Spiller W; Richmond RC; Carter AR; Langdon R; Lawlor DA; Walters RG; Vimaleswaran KS; Anderson A; Sandu MR; Tilling K; Davey Smith G; Martin RM; Relton CL;
    Cancer Causes Control; 2022 May; 33(5):631-652. PubMed ID: 35274198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the consequences of education inequality on cardiovascular disease: mendelian randomisation study.
    Carter AR; Gill D; Davies NM; Taylor AE; Tillmann T; Vaucher J; Wootton RE; Munafò MR; Hemani G; Malik R; Seshadri S; Woo D; Burgess S; Davey Smith G; Holmes MV; Tzoulaki I; Howe LD; Dehghan A
    BMJ; 2019 May; 365():l1855. PubMed ID: 31122926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung function and cardiovascular disease: a two-sample Mendelian randomisation study.
    Higbee DH; Granell R; Sanderson E; Davey Smith G; Dodd JW
    Eur Respir J; 2021 Sep; 58(3):. PubMed ID: 33574079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals.
    Thomassen JQ; Tolstrup JS; Benn M; Frikke-Schmidt R
    Epidemiol Psychiatr Sci; 2020 Apr; 29():e118. PubMed ID: 32326995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease consequences of higher adiposity uncoupled from its adverse metabolic effects using Mendelian randomisation.
    Martin S; Tyrrell J; Thomas EL; Bown MJ; Wood AR; Beaumont RN; Tsoi LC; Stuart PE; Elder JT; Law P; Houlston R; Kabrhel C; Papadimitriou N; Gunter MJ; Bull CJ; Bell JA; Vincent EE; Sattar N; Dunlop MG; Tomlinson IPM; Lindström S; ; Bell JD; Frayling TM; Yaghootkar H
    Elife; 2022 Jan; 11():. PubMed ID: 35074047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mendelian randomization: potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes.
    He W; Castiblanco J; Walter EA; Okulicz JF; Ahuja SK
    Curr Opin HIV AIDS; 2010 Nov; 5(6):545-59. PubMed ID: 20978399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mendelian Randomization and Type 2 Diabetes.
    Swerdlow DI
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):51-7. PubMed ID: 26809778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the causal effects between subjective wellbeing and cardiometabolic health: mendelian randomisation study.
    Wootton RE; Lawn RB; Millard LAC; Davies NM; Taylor AE; Munafò MR; Timpson NJ; Davis OSP; Davey Smith G; Haworth CMA
    BMJ; 2018 Sep; 362():k3788. PubMed ID: 30254091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mendelian randomisation: a tool for assessing causality in observational epidemiology.
    Sheehan NA; Meng S; Didelez V
    Methods Mol Biol; 2011; 713():153-66. PubMed ID: 21153618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex-specific Mendelian randomisation to assess the causality of sex differences in the effects of risk factors and treatment: spotlight on hypertension.
    de Ruiter SC; Schmidt AF; Grobbee DE; den Ruijter HM; Peters SAE
    J Hum Hypertens; 2023 Aug; 37(8):602-608. PubMed ID: 37024639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of genetic variation to separate the effects of early and later life adiposity on disease risk: mendelian randomisation study.
    Richardson TG; Sanderson E; Elsworth B; Tilling K; Davey Smith G
    BMJ; 2020 May; 369():m1203. PubMed ID: 32376654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the linear and non-linear association of HbA
    Luo S; Au Yeung SL; Schooling CM
    Diabetologia; 2021 Nov; 64(11):2502-2510. PubMed ID: 34345974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An introduction to Mendelian randomization with applications in neurology.
    Allman PH; Aban IB; Tiwari HK; Cutter GR
    Mult Scler Relat Disord; 2018 Aug; 24():72-78. PubMed ID: 29960142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations.
    Hu Q; Hao P; Liu Q; Dong M; Gong Y; Zhang C; Zhang Y
    Sci China Life Sci; 2019 Jun; 62(6):758-770. PubMed ID: 31104264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development.
    Holmes MV; Richardson TG; Ference BA; Davies NM; Davey Smith G
    Nat Rev Cardiol; 2021 Jun; 18(6):435-453. PubMed ID: 33707768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study.
    van der Laan SW; Fall T; Soumaré A; Teumer A; Sedaghat S; Baumert J; Zabaneh D; van Setten J; Isgum I; Galesloot TE; Arpegård J; Amouyel P; Trompet S; Waldenberger M; Dörr M; Magnusson PK; Giedraitis V; Larsson A; Morris AP; Felix JF; Morrison AC; Franceschini N; Bis JC; Kavousi M; O'Donnell C; Drenos F; Tragante V; Munroe PB; Malik R; Dichgans M; Worrall BB; Erdmann J; Nelson CP; Samani NJ; Schunkert H; Marchini J; Patel RS; Hingorani AD; Lind L; Pedersen NL; de Graaf J; Kiemeney LA; Baumeister SE; Franco OH; Hofman A; Uitterlinden AG; Koenig W; Meisinger C; Peters A; Thorand B; Jukema JW; Eriksen BO; Toft I; Wilsgaard T; Onland-Moret NC; van der Schouw YT; Debette S; Kumari M; Svensson P; van der Harst P; Kivimaki M; Keating BJ; Sattar N; Dehghan A; Reiner AP; Ingelsson E; den Ruijter HM; de Bakker PI; Pasterkamp G; Ärnlöv J; Holmes MV; Asselbergs FW
    J Am Coll Cardiol; 2016 Aug; 68(9):934-45. PubMed ID: 27561768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mendelian randomization in pharmacogenomics: The unforeseen potentials.
    Khasawneh LQ; Al-Mahayri ZN; Ali BR
    Biomed Pharmacother; 2022 Jun; 150():112952. PubMed ID: 35429744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.